A Single-center, Open-label, Randomized, Three-way, Crossover Trial to Evaluate the Bioavailability of Brexpiprazole (OPC-34712) Orally Disintegrating Tablets Relative to Brexpiprazole (OPC-34712) Conventional Tablets in Healthy Male Subjects

Trial Profile

A Single-center, Open-label, Randomized, Three-way, Crossover Trial to Evaluate the Bioavailability of Brexpiprazole (OPC-34712) Orally Disintegrating Tablets Relative to Brexpiprazole (OPC-34712) Conventional Tablets in Healthy Male Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Agitation; Major depressive disorder; Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Otsuka Pharmaceutical
  • Most Recent Events

    • 19 Dec 2016 Status changed from recruiting to active, no longer recruiting.
    • 18 Dec 2016 Planned End Date changed from 1 Nov 2016 to 1 May 2017.
    • 18 Dec 2016 Planned primary completion date changed from 1 Nov 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top